Ionis to hold first quarter 2021 financial results webcast
CARLSBAD, Calif., April 21, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, May 5th at 11:30 a.m. Eastern Time to discuss its first quarter 2021 financial results and report on pipeline and business progress.
About Ionis Pharmaceuticals, Inc. For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry leading neurological and cardiometabolic franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming one of the most successful biotechnology companies.
To learn more about Ionis visit www.ionispharma.com and follow us on Twitter @ionispharma.
Sensi.AI, a leader in AI-native, data, and analytics in senior care, today announced the appointment of in-home care leader Bob Roth to its Advisory Board. This partnership is an exciting validation of Sensi.AI's promise to enhance proactive,...
Three major challenges poised to confront the nation's clinical laboratories, genetic test companies, and anatomic pathology laboratories will be major topics when a top-flight roster of lab experts, innovators, and lab leaders gather in New Orleans...
Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that second quarter of fiscal year 2024 financial results will be released before the market opens on Wednesday,...
Merck , known as MSD outside the United States and Canada, announced that Health Canada has granted approval of KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing-chemotherapy, for the...
Globe Life Inc. will release First Quarter 2024 earnings after the market closes on Monday, April 22, 2024. At that time, a copy of the Company's First Quarter 2024 earnings press release and any other financial and statistical information about...
GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced US Food and Drug Administration (FDA) has granted the clinical trial approval for GFH925 (KRAS G12C inhibitor) in a...
